NCT02312102 2026-01-16
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed
Clinical Trials
23 trialsNCT04490707 2022-03-24
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
Zhongda Hospital
Phase 3 Unknown
NCT01433965 2022-03-10
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
University of California, Davis
Phase 1 Completed
NCT01578954 2022-01-27
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00831766 2020-12-22
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01246622 2020-09-24
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT02472691 2020-05-28
AZALENA
Heinrich-Heine University, Duesseldorf
Phase 2 Completed
NCT01619761 2020-02-11
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT01743859 2019-10-08
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
University of Colorado, Denver
Phase 2 Completed
NCT01904643 2018-10-29
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 1 Terminated
NCT00890929 2018-06-18
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Stanford University
Phase 1/2 Completed
NCT01442714 2018-01-03
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Stanford University
Phase 2 Terminated
NCT00466895 2017-11-14
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02255162 2017-08-18
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
Massachusetts General Hospital
Phase 1 Terminated
NCT01038635 2017-02-10
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01301820 2016-03-16
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)
French Innovative Leukemia Organisation
Phase 2 Completed
NCT01016600 2015-09-07
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1/2 Completed
NCT02525250 2015-08-17
Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide
Institut Paoli-Calmettes
Phase NA Completed
NCT00885508 2015-04-24
GFM-Chimio-Rev
Groupe Francophone des Myelodysplasies
Phase 2 Unknown
NCT00923234 2013-12-18
AZALE
Technische Universität Dresden
Phase 1 Terminated
NCT00720850 2013-09-27
LENAMAINT
Technische Universität Dresden
Phase 2 Terminated
NCT00360672 2013-08-14
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00839059 2011-07-29
Lenalidomide In Patients With Acute Myeloid Leukemia
University of Ulm
Phase 1 Terminated